Modulation Of Gain-Of-Function Î±6*-Nicotinic Acetylcholine Receptor By Î²3 Subunits by Dash, Bhagirathi & Lukas, Ronald J.
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center 
Barrow - St. Joseph's Scholarly Commons 
Neurobiology 
4-20-2012 
Modulation Of Gain-Of-Function Î±6*-Nicotinic Acetylcholine 
Receptor By Î²3 Subunits 
Bhagirathi Dash 
Ronald J. Lukas 
Barrow Neurological Institute, ronald.lukas@dignityhealth.org 
Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology 
Recommended Citation 
Dash, Bhagirathi and Lukas, Ronald J., "Modulation Of Gain-Of-Function Î±6*-Nicotinic Acetylcholine 
Receptor By Î²3 Subunits" (2012). Neurobiology. 249. 
https://scholar.barrowneuro.org/neurobiology/249 
This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been 
accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. 
For more information, please contact molly.harrington@dignityhealth.org. 
Modulation of Gain-of-function 6*-Nicotinic Acetylcholine
Receptor by 3 Subunits*
Received for publication,November 9, 2011, and in revised form, January 27, 2012 Published, JBC Papers in Press, February 7, 2012, DOI 10.1074/jbc.M111.322610
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Background: Function of physiologically important 63*-nicotinic receptor (nAChR) is differentially impacted by 3
subunits.
Results: nAChR expressed in several novel ways indicates that 3 subunits mostly potentiate gain-of-function 6*-nAChR.
Conclusion: Extracellular domain loop E region in 6 subunits governs effect of 3 subunit on gain-of-function 6*-nAChR.
Significance: Novel 63*-nAChR reported could be used to assess and/or develop smoking cessation aids.
We previously have shown that 3 subunits either elimi-
nate (e.g. for all-human (h) or all-mouse (m)643-nAChR)
or potentiate (e.g. for hybrid m6h4h3- or m6m4h3-
nAChR containing subunits from different species) function
of 6*-nAChR expressed in Xenopus oocytes, and that
nAChR h6 subunit residues Asn-143 and Met-145 in N-ter-
minal domain loop E are important for dominant-negative
effects of nAChR h3 subunits on h6*-nAChR function.
Here, we tested the hypothesis that these effects of 3 sub-
units would be preserved even if nAChR 6 subunits har-
bored gain-of-function, leucine- or valine-to-serine muta-
tions at 9 or 13 positions (L9S or V13S) in their second
transmembrane domains, yielding receptors with heightened
functional activity and more amenable to assessment of
effects of 3 subunit incorporation. However, coexpression
with 3 subunits potentiates rather than suppresses function
of all-human, all-mouse, or hybrid 6(L9S or V13S)4*- or
6(N143DM145V)L9S2*-nAChR. This contrasts with the
lack of consistent function when 6(L9S or V13S) and 2 sub-
units are expressed alone or in the presence of wild-type 3
subunits. These results provide evidence that gain-of-func-
tion h6h2*-nAChR (i.e. h6(N143DM145V)L9Sh2h3
nAChR) could be produced in vitro. These studies also indi-
cate that nAChR 3 subunits can be assembly partners in
functional 6*-nAChR and that 9 or 13 mutations in the
nAChR 6 subunit second transmembrane domain can act as
gain-of-function and/or reporter mutations. Moreover, our
findings suggest that 3 subunit coexpression promotes
function of 6*-nAChR.
Nicotinic acetylcholine receptors (nAChR)3 are pentam-
eric ligand-gated ion channels expressed throughout the
nervous system. Those other than the muscle-type (embry-
onic 11- or adult 11-) nAChR are thought to be
composed of different permutations of eight  subunits (2-
7, 9-10) and three  subunits (2-4) in humans (1). Of
specific interest to us in this study are 63*-nAChR (where
* indicates the known or possible presence of nAChR sub-
units other than those specified) (2–4). 63*-nAChR have
been implicated in dopaminergic neurotransmission, nico-
tine dependence, anxiety, and other important neurophysi-
ological processes (5–13).
In vitro expression of functional, all-mouse (m) or all-human
(h), wild-type 63*-nAChR has been difficult to achieve
despite strong evidence for expression of 63*-nAChR in
rodent brain (3, 4, 6, 7, 10, 12–15). Functional expression of
6*-nAChR only has been achieved in Xenopus oocytes when
using specific forms ofmutant or chimeric subunits or in hybrid
6*-nAChR composed of subunits from different species (16–
20). For example, function is achieved when chimeric, h6/h3
subunits (composed of the N-terminal, first extracellular
domain of the h6 subunit fused to the first transmembrane
domain through to theC terminus of the h3 subunit) are coex-
pressed with h2 or h4 subunits alone or in the presence of
h3 subunits (19). 6*-nAChR are functional when expressed
as hybrids of mouse and human 6 and other subunits, and
there is function of some complexes containing 3 subunits
mutated at specific residues in their second transmembrane
domains (leucine- or valine-to-serine mutations at 9 or 13
positions; L9S or V13S) to confer gain-of-function effects (4,
15, 21). Potentiation of function is sometimes seen when wild-
type 3 subunits are incorporated into hybrid complexes, but
this is in contrast to dominant-negative effects of coexpression
with wild-type 3 subunits on function of 64*-nAChR when
all subunits are from the same species (4, 21). Theremay be host
cell specificity in some of these effects because nAChR h3
subunits promote expression and nicotine-induced up-regula-
tion of h6*-nAChR in transfected cell lines (22).
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We and others have taken advantage of gain-of-function
mutations in the nAChR 3 subunit to produce functional
nAChR, including those containing 6 subunits, in part to
assess capabilities of subunits to coassemble, but also as a strat-
egy to increase functional gain (signal:noise) to facilitate such
assessments (4, 15, 21). For example, coexpression with 3V9S
subunits increases agonist sensitivity and efficacy for 6*-
nAChR.We hypothesized that similar mutations in nAChR 6
subunits would increase agonist sensitivity and efficacy of
6(L9S or V13S)(4 or 2)*-nAChR to provide enough func-
tional gain to facilitate evaluation of effects of wild-type 3
subunits on complexes and even to ensure that we can detect
incorporation of wild-type 3 subunits into 6(L9S or V13S)*-
nAChR. We also hypothesized that wild-type 3 subunits
would have the same effects, dominant-negative or potentiat-
ing, depending on the subunit combination investigated, on
gain-of-function 6(L9S or V13S)*-nAChR as they did on wild-
type6*-nAChR. This would help us assess whether any reduc-
tion or abolishment of function is due to altered open channel
probability (21) or due to reduced surface expression of nAChR
because 3 subunit incorporation facilitates formation of
dead end intermediates (23). Our results indicated that
whenever nAChR 3 subunits are incorporated into (6
or h6(N143DM145V))(L9S or V13S)*-nAChR, function is
potentiated (i.e. there is higher agonist potency and largermag-
nitude responses) irrespective of whether there are dominant-
negative or potentiating effects of 3 subunits on wild-type
6*-nAChR.
EXPERIMENTAL PROCEDURES
Chemicals—All chemicals for electrophysiology were ob-
tained from Sigma. Fresh stock solutions of nicotine ormecam-
ylamine were made daily in Ringer’s solution and were diluted
as needed.
Subcloning, Mutagenesis, and in Vitro Transcription of
nAChR Subunits—Human or mouse nAChR 6, 2, 3, or 4
subunits were subcloned into the oocyte expression vector,
pGEMHE, as earlier (4, 15). Fully synthetic, nAChR h2 sub-
unit GenBank JN565027 with nucleotide sequence optimized
for better heterologous expression (h2opt) was generated
(GENEART, Burlingame, CA) and subcloned into the pCI vec-
tor (Promega, San Luis Obispo, CA) as earlier (4). Mutations in
the nAChR subunits were introduced in the pGEMHE back-
ground using the QuikChange II site-directed mutagenesis kit
(Stratagene, La Jolla, CA). Oligonucleotides used for a creation
of the 9mutant in the h6 subunit (L9S; L280S) were 5-cgc-
tttgtatttcagtcctgtcttctctgactgtgtttttgc-3 (forward) and 5-gca-
aaaacacagtcagagaagacaggactgaaatacaaagcg-3 (reverse). Simi-
larly, oligonucleotides used for creation of the 9mutant in the
m6 subunit (L9S; L280S) were 5-ctctttgcatctccgttctgagttct-
ctcactgtctttttgc-3 (forward) and 5-gcaaaaagacagtgagagaactc-
agaacggagatgcaaagag-3 (reverse). Also, a 13 mutation in the
m6 subunit (V13S; V284S) was created by using 5-cgttctgc-
tttctctcactagctttttgctggtgattacag-3 (forward) and 5-ctg-
taatcaccagcaaaaagctagtgagagaaagcagaacg-3 (reverse) oligonu-
cleotides. Mutations in the N-terminal domain of the nAChR
h6 subunit (i.e. N143DM145V) were introduced as earlier
(4, 15). This h6 subunit mutant (i.e. N143DM145V) was
further subjected to a 9mutation using the primers stated ear-
lier. Identities of all wild-type or mutant subunits were con-
firmed by sequencing referenced to nucleotide/protein
sequences available in GenBank.
All pGEMHE plasmids were linearized immediately down-
stream of the 3-polyadenylation sequence. NheI was used
to linearize nAChR h6, h6L9S, h6(N143DM145V),
h6(N143DM145V)L9S, h3, h4, m6, m6L9S, m6L13S,
m2,m3, andm4 subunit-containing plasmids, and SbfI was
used for linearizing the h2 subunit-containing plasmid.
SwaI was used to linearize h2opt. Capped mRNA was tran-
scribed from linearized plasmids in a reaction mixture (25
l) containing 1 transcription buffer, 1.6 mM rNTPs (Pro-
mega, WI), 0.5 mM m7G(5)ppp(5)G RNA Cap Structure
Analog (New England Biolabs), 1 l of RNasin plus (New
England Biolabs) and 1 l T7 RNA polymerase (New Eng-
land Biolabs) following standard protocols or using
mMESSAGE mMACHINE T7 kit (Ambion/Invitrogen)
and following the manufacturer’s instructions. The integ-
rity and quality of the cRNAwere checked by electrophoresis
and UV spectroscopy.
Oocyte Preparation and cRNA Injection—Female Xenopus
laevis (Xenopus I, AnnArbor,MI) were anesthetized using 0.2%
tricaine methanesulfonate (MS-222). The ovarian lobes were
surgically removed from the frogs and placed in an incubation
solution that consisted of (in mM) 82.5 NaCl, 2.5 KCl, 1 MgCl2,
1 CaCl2, 1 Na2HPO4, 0.6 theophylline, 2.5 sodium pyruvate, 5
HEPES supplemented with 50 mg/ml gentamycin, 50 units/ml
penicillin, and 50 g/ml streptomycin; pH 7.5. The frogs were
allowed to recover from surgery before being returned to the
incubation tank. Ovarian lobes were cut into small pieces and
digested with 0.08 Wu¨nsch units/ml Liberase blendzyme 3
(Roche Applied Science) with constant stirring at room tem-
perature for 1.5–2 h. The dispersed oocytes were thoroughly
rinsed with incubation solution. Stage VI oocytes were selected
and incubated at 16 °C before injection. Micropipettes used for
injection were pulled from borosilicate glass (Drummond Sci-
entific, Broomall, PA) using a Sutter P87 horizontal puller, and
the tips were broken with forceps to 40 m in diameter.
cRNA was drawn up into the micropipette and injected into
oocytes using a Nanoject microinjection system (Drummond
Scientific) at a total volume of 60 nl. To express nAChR in
oocytes, about 4 ng of cRNAcorresponding to each subunit was
injected; i.e. at ratios of 1:1 or 1:1:1 for binary or trinary recep-
tors, respectively, with the exception that for coexpression of
h6(N143DM145V)h2*-nAChR in the presence or
absence nAChRh3 subunit, about 10 ng of cRNAcorrespond-
ing to each subunit including nAChR h2opt subunit was
injected.
Oocyte Electrophysiology—Two to seven days after injection,
oocytes were placed in a small-volume chamber and continu-
ously perfused with oocyte Ringer’s solution, which consisted
of (in mM) 92.5 NaCl, 2.5 KCl, 1 CaCl2, 1 MgCl2, and 5 HEPES;
pH 7.5. The chamber was grounded through an agarose bridge.
The oocytes were voltage-clamped at 70 mV (unless other-
wise noted) to measure agonist-induced currents using an
AxoClamp 900A and the pClamp 10.2 software (Axon Instru-
ments, CA). The current signal was low pass-filtered at 10 Hz
Gain-of-function6*-Nicotinic Receptor and3 Subunits
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with the built-in low pass Bessel filter in the AxoClamp 900A
and digitized at 20 Hz with an Axon Digidata1440A and the
pClamp10.2 software. Electrodes contained 3 M KCl and had a
resistance of 1–2 megaohms. Drugs (agonists and antagonists)
were prepared daily in bath solution. Drug was applied using a
Valvelink 8.2 perfusion system (Automate Scientific, Berkeley,
CA). All electrophysiologicalmeasurementswere conducted or
checked in at least two batches of oocytes.
Experimental Controls—Injection of water or empty vector
(used as two forms of negative controls) or of cRNA corre-
sponding to one subunit alone or pairwise combinations of
3 subunits with either an 6 or a mutant 6 subunit or 2 or
4 subunits (8–20 ng total of cRNA) did not result in the
expression of functional nAChR. Current responses to 100 M
nicotine were less than 5–10 nA (data not shown).
Data Analyses—Raw data were collected and processed in
part using pClamp 10.2 (Molecular Devices, Sunnyvale, CA)
and a spreadsheet (Excel; Microsoft, Bellevue,WA), using peak
current amplitudes as measures of functional nAChR expres-
sion and results pooled across experiments (mean  S.E. for
data from at least three oocytes). In some cases, mean peak
current amplitudes in response to a single concentration of an
agonist were compared across different subunit combinations.
However, assessment of true Imax values for different nAChR
subunit combinations required assessment based on more
complete concentration-response relationships, inwhichmean
peak current amplitudes at specified ligand concentrations
were fit to the Hill equation or its variants using Prism 4
(GraphPad Software, SanDiego, CA). F-tests (p 0.05 to define
statistical significance) were carried out to compare the best fit
values of log molar EC50 values across specific nAChR subunit
combinations.
There are limitations in the ability to compare levels of
functional nAChR expression, although we injected similar
amounts of RNA for all constructs. This is because expres-
sion levels assessed as peak current amplitudes are affected
by batch-to-batch variation in oocytes, time between cRNA
injection and recording, and subunit combination-specific
parameters, such as open probability (influenced by gating
rate constants, rates, and extents of desensitization), single
channel conductance, assembly efficiency, and efficiency of
receptor trafficking to the cell surface (24). We made no
attempt to measure or control for subunit combination-spe-
cific effects, but whenever preliminary studies revealed pos-
sible differences in peak current amplitudes, findings were
further confirmed across different subunit combinations
using the same batch of oocytes and the same time between
cRNA injection and recording. Peak current amplitudes
shown from representative traces in some figures presented
below, pooled data from limited sets of studies, and mean
peak current amplitudes across all studies for a given com-
bination of subunits given in tables sometimes differ. How-
ever, when we make statements about results comparing
ligand potencies and peak current amplitudes across subunit
combinations, we do so for studies done under the same or
very similar conditions, and the observations are clear, sta-
tistically significant, and in agreement whether for pooled
data or for results from smaller sets of studies (one-way anal-
yses of variance followed by Tukey’s multiple comparison
tests).
RESULTS
Human nAChR 6L9S Subunits Form Functional Receptors
in Association with nAChR h4 and h3 Subunits with
Increased Receptor Agonist Sensitivity and Efficacy—Earlier, we
observed that oocytes coinjected with nAChR h6 and h4
subunit cRNAs produce functional h6h4-nAChR in only a
few out of many injected oocytes and then only have minimal
responses to nicotinic agonists (4). Although we couldmeasure
a peak current of 22 3 nA for h6h4-nAChR in response to
100 M acetylcholine, we were unable to measure reliable and
reproducible functional responses to nicotine. Also, oocytes
injected with nAChR h6, h4, and h3 subunit cRNAs do not
produce reliable and reproducible functional h6h4h3-
nAChR, suggesting that the small amount of function seen for
h6h4-nAChR is either reduced or completely eliminated,
probably due to 3 subunits exerting a negative effect on func-
tion of h6h4*-nAChR. We replicated those findings in the
current work, and we also found that oocytes coexpressing
nAChR h6L9S and h4 subunit cRNAs have marginally
increased, but more reproducible, responses to nicotine (peak
current of 32 7 nA for h6L9Sh4-nAChR in response to 100
M nicotine; Fig. 1; Table 1). Thus, replacement of h6L9S for
h6 subunits does not have as great of a gain-of-function effect
on 64*-nAChR as does introduction of h3V9S subunits (4)
into otherwise wild-type h6h4*-nAChR.
Consistent with our previous observations regarding intro-
duction of gain-of-function 3 subunits into 6*-nAChR (4),
oocytes coexpressing nAChR h6L9S and h4 subunits and
exposed to the nAChR noncompetitive antagonist and open
channel blocker, mecamylamine, respond with an apparent
outward peak current of 12 5 nA (Table 1). Because mecam-
ylamine coexposure more than blocks inward currents pro-
duced by nicotinic agonists, also leading under those conditions
to production of apparent outward current responses, and does
so in a concentration-dependent manner, we again interpret
these effects as showing the ability of mecamylamine to block
spontaneous opening of 6L9Sh4-nAChR channels (Table 1).
Given the magnitudes of peak current responses to nicotine
alone and to mecamylamine alone, about 27% of h6L9Sh4-
nAChR appear to be spontaneously open at any given time (12/
(12 32) 0.27).
When nAChR h6L9S and h4 were coexpressed with h3
subunits instead of alone, oocyte responsiveness to nicotine
(EC50 value of 0.9 M) increases over 10-fold (to a peak current
response of 350  52 nA; Fig. 1, Table 1). This suggests that
wild-type 3 subunits incorporate into h6L9Sh4*-nAChR
and strongly potentiate receptor function. However, this does
not occur with a change in agonist potency upon h3 subunit
incorporation into h6L9Sh4*-nAChR because there is not a
significant change in nicotine EC50 values (Table 1). Outward
current production in the same oocytes (9.5  1.5 nA) in
response to 1000 M mecamylamine indicates that there is
spontaneous opening of h6L9Sh4h3-nAChR, but levels
of spontaneous opening are comparable with those for
h6L9Sh4-nAChR in the absence of h3 subunits, indicating
Gain-of-function6*-Nicotinic Receptor and3 Subunits
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that a smaller proportion of h6L9Sh4h3-nAChR is sponta-
neously open at any time (9.5/(9.5 350) 0.026; Table 1) than
for h6L9Sh4-nAChR. No function was observed in response
to nicotine or mecamylamine in oocytes coexpressing nAChR
h6 or h6L9S subunits plus h2 subunits with or without h3
subunits.
Mouse nAChR 6V13S Subunits Form Functional Receptors
in Association with nAChR m4 and m3 Subunits with
Increased Receptor Agonist Sensitivity and Efficacy—We have
shown earlier that oocytes coinjected with m6 and m4
nAChR subunit cRNAs form functional nAChR, but with min-
imal responses to nicotinic agonists, and function is further
reduced in the presence of nAChR m3 subunits, indicating
that nAChR m3 subunits exert dominant-negative effects on
the function of m6m4*-nAChR (4). Here, we observed that
oocytes coexpressing either wild-type m6 or mutant m6L9S
along withm4 subunits give comparably modest peak current
responses to 100 M nicotine (Imax  27  7 or 29  1 nA,
respectively; Table 1). Thus, although oocytes expressing
m6L9S and m4 subunits give outward current responses to
mecamylamine, consistent with spontaneous channel opening,
the 9 mutation in the nAChR m6 subunit does not signifi-
cantly increase the magnitude of functional responsiveness
(Table 1). Similarly, there is no increase in functional respon-
siveness to nicotine for oocytes coexpressing nAChR m6L9S,
m4, and m3 subunits (peak current 26 4 nA), although
FIGURE1.Functionalpropertiesofh6*-nAChR.A, representative traces are shown for inward currents inoocytesheld at70mV, responding toapplication
at the indicated concentrations of nicotine (shownwith the duration of drug exposure as black bars above the traces), and expressing nAChR h6L9S and h4
subunits (i) or nAChR h6L9S, h4, and h3 subunits (ii). B, results for these and other studies averaged across experiments were used to produce concentra-
tion-response curves (ordinate,meannormalized current S.E.; abscissa, ligand concentration in logM) for inward current responses to nicotine as indicated
for oocytes expressing nAChRh6L9S andh4 subunits alone (f) orwith h3 subunits (), where current amplitudes are represented as a fraction of the peak
inward current amplitude in response to themost efficacious concentrationofnicotine.Muchhigher levels of evokedcurrents are evident for functional nAChR
containing h6L9S, h4, and h3 subunits when compared with receptors lacking h3 subunits. See Table 1 for parameters.
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mecamylamine-induced outward current indicated that there
is spontaneous opening of m6L9Sm4m3-nAChR (Table 1).
By contrast, unexpectedly, and interestingly, oocytes ex-
pressing nAChR m6V13S, m4, and m3 subunits exhibit a
	25-fold increase in peak current responses to nicotine (800
190 nA) relative to responses of m6L9Sm4- or
m6L9Sm4m3-nAChR. Also, we were able to define an
increase in nicotine potencywhen acting atm6V13Sm4m3-
nAChR (EC50  1.2 M) relative to nicotine potency at
m6m4-nAChR (EC50 value of 26 M; Table 1, Fig. 2).
In addition, there also is spontaneous opening of
m6V13Sm4m3-nAChR, although responses to nicotine or
mecamylamine are absent for m6V13Sm4-nAChR (Table 1).
No function was observed in response to nicotine or mecamyl-
amine in oocytes coexpressing nAChR m6 or m6L9S or
m6V13S subunits plus m2 subunits with or without m3
subunits.
Mouse nAChR 6L9S Subunits Form Functional Receptors in
Association with nAChR h4 and h3 Subunits with Increased
Receptor Agonist Sensitivity and Efficacy—We reported earlier
that oocytes coinjected with nAChR m6, h4, and h3 sub-
unit cRNAs tend to form functional m6h4h3-nAChR,
whereas oocytes coexpressing nAChR m6 and h4 subunit
cRNAs do not respond to nicotinic agonists (4). Here, we show
that oocytes coexpressing nAChR m6L9S and h4 subunits
yield peak function of 80 18 nA in response to 100 M nico-
tine (Fig. 3, Table 1) and outward current responses (12 9 nA)
to mecamylamine, consistent with spontaneous channel open-
ing of m6L9Sh4-nAChR (Table 1). Moreover, oocytes coex-
pressing nAChR m6L9S, h4, and h3 subunits respond to
nicotine with an EC50 value of 2.3 M and give an even larger
peak current (870  270 nA; Fig. 3; Table 1). Also, oocytes
coexpressing m6L9S, h4, and h3 subunits give relatively
large, outward current responses (peak current of 41 15 nA)
TABLE 1
Parameters for agonist or antagonist action at nAChR containing gain-of-function 6mutant subunits
Potencies (micromolar EC50 or IC50 valueswith 95% confidence intervals), Hill coefficients (nH S.E.),mean S.E. efficacies (two-electrode voltage-clamppeak responses, Imax, in
nanoamperes), and concentrations where maximal peak current amplitudes (Imax concentration in micromolar) are achieved (M) are provided for nicotine as an agonist or
mecamylamineas anantagonist actingatnAChRcomposedof the indicated subunitsderived fromthe specified species and fromthe indicatednumberof independent experiments
(n) based on studies as shown the figures. Closed up arrows or closed down arrows indicate a significant (p 0.05) increase or decrease, respectively, in potency or efficacy of the
indicated agent at the indicated nAChR subtype relative to nAChR containing the wild type 6 subunit. Filled triangle indicates a significant increase in indicated agonist or
antagonist potency or efficacy at the indicated nAChR containing 6L9S or 6V13S subunits relative to the same complex but lacking 3 subunits.Open up arrows or open down
arrows indicate a significant increase or decrease, respectively, in potency or efficacy of the indicated agonist at the indicated nAChR containing6V13S subunits relative to nAChR
containing6L9S subunits.Note thatnoor very rare and then small responses tonicotinewere seen for the following subunit combinations (n6–9each): h6orh6L9S plush2
alone or with h3; m6 or m6L9S or m6V13S plus m2 alone or with m3 or h3; and m6 or m6L9S plus h2 alone or with h3. - indicates that absent or inconsistent
functional responses in two-electrode voltage-clamp studies precluded determination of the parameter of interest; # indicates data from (4).
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to mecamylamine, again an indication that functional and
spontaneously opening m6L9Sh4h3-nAChR are formed
(Table 1). The kinetics of traces generated in response to
application of nicotine differs between m6L9Sh4- and
m6L9Sh4h3-nAChR. m6L9Sh4h3-nAChR in response
to activation by 1000 M nicotine exhibit a tail current that is
significantly reduced or absent in m6L9Sh4-nAChR when
activated by the same concentration of nicotine. Precisely, in
the presence of h3 subunits, there is a pronounced functional
block of the receptor at higher concentration of nicotine.
Removal of the functional block imposed by nicotine (probably
acting as an open channel blocker), as a result of switching out
to buffer application, leads to activation of the receptor by the
residual nicotine that results in formation of a tail current. This
is not unusual given that incorporation of accessory subunits
into nAChR differentially affects various functional character-
istics of the receptor (25).
Minimal and inconsistent nAChR function was observed
when m6L9S subunits were coexpressed with h2 and h3
subunits. This is in contrast to our earlier observation that
nAChR m6 subunits along with h2 subunits and gain-of-
function h3 subunits (h3V9S; h3V273S) form functional
m6h2h3V9S-nAChR (4). This suggests that the gain-of-
functionmutation in them6L9S subunit is inadequate to over-
come what seems to be a strong, dominant-negative effect of
nAChR 3 subunits in the presence of 2 subunits.
Mouse nAChR 6L9S Subunits Form Functional Receptors in
Association with nAChRm4 and h3 Subunits with Increased
Receptor Agonist Sensitivity and Efficacy—Oocytes coinjected
with nAChR m6, m4, and h3 subunit. cRNAs give 	10-
fold larger and2-fold more sensitive responses to nicotinic
agonists than do oocytes coinjected m6 and m4 subunit
cRNAs and in stark contrast to the elimination of functional
responses in oocytes coexpressing nAChR m6, m4, and
m3 subunits (Table 1). Interestingly, here we found that
oocytes coexpressing nAChR m6L9S, m4, and h3 sub-
units responded to nicotine with an EC50 value of 0.48 M
andwith large peak currents 680 32 nA; Fig. 4; Table 1) and
gave outward current responses (8.5  3.3 nA) when
exposed to 1000 M mecamylamine (Table 1). No function
was observed when m6L9S subunits were coexpressed with
m2 and h3 subunits.
Human nAChR 6(N143DM145V)L9S Subunits Form
Functional Receptors in Association with nAChR h2 and h3
Subunits with Increased Receptor Agonist Sensitivity and
Efficacy—Earlier (4), we had shown that mutations in the
N-terminal domain of the nAChR h6 subunit enable
nAChR h3V9S subunits to exert a gain-of-function effect
at h6(N143DM145V)h2*-nAChR (i.e. h6(N143D
M145V)h2h3V9S-nAChR are functional). This finding
led us to explore effects of incorporation of h3 subunits
into h6(N143DM145V)L9Sh2*-nAChR.
FIGURE 2. Functional properties of m6*-nAChR. A, representative traces are shown for inward currents in oocytes held at70mV, responding to applica-
tion at the indicated concentrations of nicotine (shown with the duration of drug exposure as black bars above the traces), and expressing nAChR m6V13S,
m4, and m3 subunits. B, results for these and other studies averaged across experiments were used to produce concentration-response curves (ordinate,
mean normalized current S.E.; abscissa, ligand concentration in logM) for inward current responses to nicotine as indicated for oocytes expressing nAChR
m6 and m4 subunits (f) or m6V13S and m4 and m3 subunits (), where current amplitudes are represented as a fraction of the peak inward current
amplitude in response to the most efficacious concentration of nicotine. Much higher levels of evoked currents are evident for functional nAChR containing
m6V13S, m4, and m3 subunits when compared with receptors lacking m6V13S subunits. See Table 1 for parameters.
Gain-of-function6*-Nicotinic Receptor and3 Subunits
14264 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 17•APRIL 20, 2012
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Oocytes injectedwith nAChRh6(N143DM145V)L9S and
h2 subunit cRNAs did not yield functional nicotinic responses
(Table 1). However, oocytes injected with h3 subunit cRNAs
along with nAChR h6(N143DM145V)L9S and h2 subunit
cRNAs yielded functional responses. Oocytes coexpressing
nAChR h6(N143DM145V)L9S, h2, and h3 subunits
responded to nicotine with an EC50 value of 0.02M and with a
maximal peak current of 98 21 nA (Fig. 5; Table 1). We also
found that oocytes coexpressing nAChR h6(N143D
M145V)L9S, h2, and h3 gave outward current responses
when exposed to 1000 M mecamylamine (data not shown).
DISCUSSION
Recent studies have investigated how nAChR 3 subunits
might incorporate as accessory partners into nAChR sub-
types, specifically into 6*-nAChR (4). To further under-
stand how 3 subunits might incorporate into 6*-nAChR,
we exploited the gain-of-function/reporter mutant strategy
(4, 15, 26) to reveal whether 3 subunits integrate into 6*-
nAChR complexes that are on the cell surface and func-
tional. This approach allows us to focus on cell surface, func-
tional receptors without complications due to ambiguities of
protein chemical or immunochemical studies confounded
by the prevalent expression of intracellular and perhaps par-
tially assembled receptor complexes and the unreliable qual-
ity and/or availability of most anti-nAChR antibodies for use
in immunoprecipitation and/or immunoblot studies (15). In
addition, we based the current studies on our findings (4)
that (i) incorporation of nAChR 3 subunits into 6*-
nAChR, mouse or human, has a dominant-negative effect;
(ii) incorporation of nAChR h3 subunits into m6h4*- or
m6m4*- nAChR leads to formation of functional nAChR;
and (iii) mutations in the E1 N-terminal domain of the
nAChR h6 subunit are essential for successful assembly
and formation of functional h6(N143DM145V)-
h2h3V9S-nAChR.
FIGURE 3. Functional properties of hybridm6h4*-nAChR. A, representative traces are shown for inward currents in oocytes held at70mV, responding
to application at the indicated concentrations of nicotine (shown with the duration of drug exposure as black bars above the traces), and expressing nAChR
m6L9S and h4 subunits (i) or nAChR m6L9S, h4, and h3 subunits (ii). B, results for these and other studies averaged across experiments were used to
produce concentration-response curves (ordinate, mean normalized current S.E.; abscissa, ligand concentration in log M) for inward current responses to
nicotine as indicated for oocytes expressingnAChRm6L9S andh4 subunits alone (f) orwith h3 subunits () or expressingm6 andh4 andh3 subunits
(; data from Ref. 4), where current amplitudes are represented as a fraction of the peak inward current amplitude in response to the most efficacious
concentration of nicotine.Muchhigher levels of evoked currents are evident for functional nAChR containingm6L9S, h4, andh3 subunitswhen compared
with receptors lacking h3 subunits. See Table 1 for parameters.
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The principal findings of this study, whenever functional
expression levels are adequate to allow comparisons, and with
exceptions that could be informative as discussed below, are: (i)
that introduction of 9 or 13mutations into the second trans-
membrane domain of m6 or h6 subunits typically has a
gain-of-function effect, leading to production of (6 or
6(N143DM145V))(L9S or V13S)(2 or 4)*-nAChR that
have 6–34-fold higher sensitivity to nicotine and much
higher levels of function than do nAChR containing the
same subunit combinations but with wild-type 6 sub-
units; (ii) that incorporation of 3 subunits into (6 or
6(N143DM145V))(L9S or V13S)(2 or 4)*-nAChR typically
increases levels of receptor function with or without concomi-
tant increase in agonist potency; and (iii) that gain-of-function
mutations in 6 or 6(N143DM145V) subunits still do not
allow for formation of functional 6(L9S or V13S)2-nAChR
complexes, thus continuing to confound assessments of roles
played by 3 subunits in modulation of 62*-nAChR.
The amount of functional expression for h6L9Sh4-,
m6L9Sm4-, or m6L9Sh4-nAChR is modest in absolute
terms (27–80-nA peak current). However, with the exception
of the insignificant difference in themagnitude of function seen
for all-mouse m6L9Sm4- and m6m4-nAChR, the
increase in function upon expression with the 6 subunit 9
mutants is remarkable because of the lack of reliable function
for wild-type, all human h6h4-, or hybrid m6h4-nAChR.
The little-if-any function for all-wild-type 64-nAChR com-
plicates quantitative assessment of effects of 6 subunit gain-
of-function mutations on agonist potency, although qualita-
tively, nicotine EC50 values are over 10 M for 64-nAChR
and never higher than 3.1 M for 6(L9S or V13S)4-nAChR.
However, gain-of-function effects manifest as increases in ago-
nist potency and in peak current magnitudes are very clear
based on comparisons of h6h4h3- with h6L9Sh4h3-
nAChR and comparisons of m6h4h3- withm6L9Sh4h3-
nAChR. A difference in agonist potency is also clear for compari-
son of m6m4h3- with m6L9Sm4h3-nAChR, although
there is only a 2-fold difference in peak current response across
these receptors, partly due to the relatively high absolute levels
of function for the hybrid m6m4h3-nAChR. Once again,
however, all-mouse 643-nAChR are outliers because there
is only modest function for m6L9Sm4m3-nAChR,
although there is no reliable function for the all-wild-type ana-
log, m6m4m3-nAChR.
Nevertheless, and very interestingly, for all-mouse 6*-re-
ceptors, although there is not reproducible function for
m6V13Sm4-nAChR, there are increases both in agonist
potency and in response magnitude for m6V13Sm4m3-
nAChR when compared with those parameters for any form of
m6m4-nAChR or for m6m4m3- or m6L9Sm4m3-
nAChR. Our initial studies of mouse 6*-nAChR were
prompted because of the reported difficulties in heterologous
expression of all-human 6*-nAChR and because somany data
on naturally expressed 6*-nAChR function came from studies
using rodents, but we have found all-mouse 6*-nAChR no
easier to express than human6*-nAChR. Expression of hybrid
FIGURE4.Functionalpropertiesofgain-of-functionhybridm6h3*-nAChR.A, representative traces are shown for inwardcurrents inoocytesheldat70
mV, responding to application at the indicated concentrations of nicotine (shown with the duration of drug exposure as black bars above the traces), and
expressing nAChR m6L9S, m4 and h3 subunits. B, results for these and other studies averaged across experiments were used to produce concentration-
response curves (ordinate, mean normalized current S.E.; abscissa, ligand concentration in logM) for inward current responses to nicotine as indicated for
oocytes expressing nAChRm6 andm4 subunits alone (32) or with h3 subunits (f) or expressingm6L9S andm4 and h3 subunits (), where current
amplitudes are representedas a fractionof thepeak inward current amplitude in response to themost efficacious concentrationofnicotine.Muchhigher levels
of evokedcurrents areevident for functional nAChRcontainingm6L9S, h4, andh3 subunitswhencomparedwith receptors lackingh3 subunits. SeeTable
1 for parameters.
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nAChR made up of subunits from different species has been
more productive, suggesting that subtle differences for a given
subunit across species in amino acid sequences in N-terminal,
extracellular domains, but also in cytoplasmic and perhaps
transmembrane domains, and at whatmust be at subunit inter-
faces not heretofore recognized as being functionally impor-
tant, can strongly influencewhether functional6*-nAChR can
be produced (4). The fact that m6 L9S and V13S mutations
differing in position by just one turn in the second transmem-
brane domain -helix can have such a large difference in their
impact on m6m4*-nAChR function indicates unexpectedly
important roles for this channel-lining region in 6*-nAChR
function. More work is warranted to more thoroughly charac-
terize the bases for these influences.
Our findings demonstrate that 6 subunit L9S or V13S
modifications can function as reporter and/or gain-of-function
mutations, leading to production of receptors with heightened
sensitivity to agonists, thus confirming the presence of 6 sub-
units in functional receptor complexes, as expected. These
studies also further affirm and recapture the strategy applied to
exploit gain-of-function 6 subunit mutations expressed in
vivo to enhance sensitivity to agonists and thus to help reveal
roles played by 6*-nAChR in dopaminergic pathways relevant
to movement disorders and nicotine dependence (13).
This study was also initiated largely to assess whether effects
previously described of nAChR 3 subunit incorporation into
6*-nAChR would be preserved when receptor functional lev-
els at baseline were intentionally elevated by using reporter
mutation/gain-of-function 6 subunits as coexpression part-
ners. By contrast to earlier work by others (21), in which 3
subunits were coexpressed in excess over other subunits, we
chose to introduce equal amounts of subunit cRNAs into
oocytes for the current work, anticipating that approximately
equal amounts of subunit proteins would bemade and that this
more closely approximates conditions in vivo. We confirmed
our previous observations (4, 15) that h3 subunit incorpora-
tion into h6h4*-nAChRhas an uncertain effect on functional
expression, that m3 subunit incorporation into m6m4*-
nAChR has a dominant-negative effect on receptor function,
that h3 subunit incorporation into hybrid m6h4*-nAChR
potentiates function, but that there is even larger potentiation
of function when h3 subunits are incorporated into hybrid
m6m4*-nAChR. However, with the exception of the lack of
an obvious effect of m3 subunit incorporation on low func-
tioning m6L9Sm4*-nAChR, wild-type 3 subunit incorpo-
ration into any of the tested 6(L9S or V13S)4-nAChR potenti-
ated levels of function by	11-fold, notably including effects of
h3 subunits on low functioning m6L9Sm4*-nAChR and
effects ofm3 subunits onm6V13Sm4*-nAChR. These find-
ings indicate that 3 subunits do not always have dominant-
negative effects on 6*-nAChR function as suggested earlier
(21) and do not always promote formation of dead end, 64*-
nAChR intermediates as suggested previously (23). Instead,
based on our results shown here, we can hypothesize that 3
subunits seem to promote assembly, cell surface expression,
and/or functional responsiveness of 64*-nAChR, at least
when there is enough function for 64(non-3)-nAChR to
allow assessment of effects of 3 subunit incorporation. Our
FIGURE 5. Functional properties of gain-of-function h6(N143DM145V)L9Sh3*-nAChR. A, representative traces are shown for inward currents in
oocytes held at80mV, responding to application at the indicated concentrations of nicotine (shownwith the duration of drug exposure as black bars above
the traces), and expressing nAChR h6(N143DM145V)L9S, h2, and h3 subunits. B, results for these and other studies averaged across experiments were
used to produce concentration-response curves (ordinate, mean normalized current  S.E.; abscissa, ligand concentration in log M) for inward current
responses to nicotine for oocytes expressing nAChR h6(N143DM145V)L9S, h2, and h3 subunits (E), where current amplitudes are represented as a
fraction of the peak inward current amplitude in response to themost efficacious concentration of nicotine.Much higher levels of evoked currents are evident
for functional nAChR containing h6(N143DM145V)L9S, h2, and h3 subunits when compared with receptors lacking h3 subunits. See Table 1 for
parameters.
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findings using the oocyte expression system are in line with
observationsmade regarding 3 subunit effects on 6*-nAChR
functional expression in cell lines (22), suggesting that success-
ful, functional 64*-nAChR expression in oocytes does not
require coexpression with chaperones missing from oocytes
but present in neurons or selected cell lines. Notably, although
peak current potentiation upon substitution of gain-of-func-
tion 6 subunits (or 3 subunits; see Refs. 4 and 15) occurs
along with an increase in agonist potency, wild-type 3 incor-
poration into complexes increases peak current responses
without affecting agonist potency.
In almost every case, 6(L9S or V13S)*-nAChR spend a finite
amount of time in a spontaneously open channel state, as
judged by the ability of mecamylamine to block those open
channels, giving the appearance of production of outward cur-
rents. This is a common feature for nAChR containing subunits
with second transmembrane domain mutations that give gain-
of-function effects (27, 28). Interestingly, the absolute magni-
tudes of responses tomecamylamine generally are quite similar
across all the 6*-nAChR studied (7.8–12 nA), even when
magnitudes of agonist-induced inward currents varied much
more widely (26–800 nA). The only exceptions are for
m6V13Sm4-nAChR, which curiously have no reproducible
responses to nicotine or to mecamylamine, despite there being
strong responses upon incorporation of m3 subunits to form
m6V13Sm4m3-nAChR, and for m6L9Sh4h3-nAChR,
which have slightly larger responses to mecamylamine (41 nA)
but also have the largest responses to nicotine (870 nA).
Although the current findings support a role for 3 subunits
in potentiating function of 64*-nAChR with at least a mod-
icum of baseline functional activity, we were confounded in our
studies of 62*-nAChR by a general lack of function. This
made it impossible to assess effects of3 subunit incorporation
on 62*-nAChR, but the results indicate that any gain-of-
function earned by incorporation of 6(L9S or V13S) subunits
into complexes is inadequate to reveal effects of 3 subunits,
perhaps due to the surprising incompatibilities (illuminated in
Refs. 4 and 15) that often occur in attempts to use6,2, and3
subunits to form functional receptors. In order for us to show
that in fact a variant of gain-of-function h6 subunit can part-
ner with h2 and h3 subunit to form functional nAChR, we
took advantage of our site-directed mutagenesis work (4, 15),
which has implicated 6 residues 143 and 145 in the ability
of 3 subunits to affect 62*-nAChR function. The
h6(N143DM145V) mutations change the indicated resi-
dues to those that are in the m6 subunit and permit mutated
h6 subunits to show function when coexpressed with h2 and
h3 subunits when wild-type h6 subunits do not. Human
nAChR 6 subunit residues 143 and 145 are in the E1 domain,
in loop E, on the () or complementary face of the subunit. This
suggests that interactions between the 6 subunit () face with
the () face from either 2 subunits or 3 subunits are impor-
tant for functional 6*-nAChR expression. In order for us to
prove that the nAChR 3 subunit does affect the function of
62*-nAChR, a 9 mutation was introduced into the
h6(N143DM145V) subunit. Although coexpression of
h6(N143DM145V)L9S and h2 subunits did not yield
receptors with reliable function, upon inclusion of the h3 sub-
unit, function was evident in all oocytes coexpressing the three
subunits together. These h6(N143DM145V)L9Sh2*-
nAChR mimic the gain-of-function, high-affinity m6*-
nAChR artificially expressed in mouse midbrain dopamine
neurons (13).
We conclude, based on the current and previous findings,
that gain-of-function/reporter mutations introduced into 6
subunits in6(2 or4)3-nAChR are effective in potentiating
receptor function. This potentiation yields receptors with
higher agonist potency and larger magnitude responses to ago-
nists, and also a finite likelihood of existing in a spontaneously
open channel state. We also conclude from the present studies
that wild-type 3 subunit incorporation into functionally com-
petent (6 or 6(N143DM145V)) (L9S or V13S)(4 or 2)*-
nAChR has a potentiating effect irrespective of whether there
are dominant-negative, null, or potentiating effects of 3 sub-
units on wild-type 6(2 or 4)*-nAChR. In fact, reliable
expression of functional gain-of-function 6*-nAChR is
achieved only in the presence of nAChR 3 subunits. These
results suggest thatwild-type3 subunit coexpression is at least
permissive for cell surface expression of 64*-nAChR and
very likely promotes function of these receptors. The strategies
and results demonstrated here to increase function of 6*-
nAChR to levels compatiblewith drug screening could facilitate
the development of new drugs selective for 6*-nAChR. This is
of increasing importance given the potentially important roles
for 6*-nAChR in movement and movement disorders, mood
disorders, and drug reinforcement (5, 13, 29–31).
Acknowledgments—We thank Dr. Jerry A. Stitzel (Department of
Integrative Physiology, University of Colorado, Boulder, CO) for pro-
viding mouse nAChR subunits. We also thank Drs. Yongchang Chang
and Paul Whiteaker of the Barrow Neurological Institute for com-
ments about the project andmanuscript and for technical advice and
Minoti Bhakta for assistance.
REFERENCES
1. Lukas, R. J., Changeux, J. P., Le Nove`re, N., Albuquerque, E. X., Balfour,
D. J., Berg, D. K., Bertrand, D., Chiappinelli, V. A., Clarke, P. B., Collins,
A. C., Dani, J. A., Grady, S. R., Kellar, K. J., Lindstrom, J. M., Marks, M. J.,
Quik, M., Taylor, P. W., andWonnacott, S. (1999) International Union of
Pharmacology. XX. Current status of the nomenclature for nicotinic ace-
tylcholine receptors and their subunits. Pharmacol. Rev. 51, 397–401
2. Capelli, A. M., Castelletti, L., Chen, Y. H., Van der Keyl, H., Pucci, L.,
Oliosi, B., Salvagno, C., Bertani, B., Gotti, C., Powell, A., andMugnaini, M.
(2011) Stable expression and functional characterization of a human nic-
otinic acetylcholine receptor with 62 properties: discovery of selective
antagonists. Br. J. Pharmacol. 163, 313–329
3. Yang, K., Buhlman, L., Khan, G.M., Nichols, R. A., Jin, G.,McIntosh, J. M.,
Whiteaker, P., Lukas, R. J., and Wu, J. (2011) Functional nicotinic acetyl-
choline receptors containing 6 subunits are on GABAergic neuronal
boutons adherent to ventral tegmental area dopamine neurons. J. Neuro-
sci. 31, 2537–2548
4. Dash, B., Bhakta, M., Chang, Y., and Lukas, R. J. (2011) Identification of
N-terminal extracellular domain determinants in nicotinic acetylcholine
receptor (nAChR) 6 subunits that influence effects of wild-type or mu-
tant 3 subunits on function of 62*- or 64*-nAChR. J. Biol. Chem.
286, 37976–37989
5. Cui, C., Booker, T. K., Allen, R. S., Grady, S. R.,Whiteaker, P., Marks,M. J.,
Salminen, O., Tritto, T., Butt, C. M., Allen, W. R., Stitzel, J. A., McIntosh,
J. M., Boulter, J., Collins, A. C., and Heinemann, S. F. (2003) The 3
Gain-of-function6*-Nicotinic Receptor and3 Subunits
14268 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 17•APRIL 20, 2012
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
nicotinic receptor subunit: a component of -conotoxinMII-binding nic-
otinic acetylcholine receptors thatmodulate dopamine release and related
behaviors. J. Neurosci. 23, 11045–11053
6. Exley, R., Clements, M. A., Hartung, H., McIntosh, J. M., and Cragg, S. J.
(2008) 6-Containing nicotinic acetylcholine receptors dominate the nic-
otine control of dopamine neurotransmission in nucleus accumbens.
Neuropsychopharmacology 33, 2158–2166
7. Meyer, E. L., Yoshikami, D., and McIntosh, J. M. (2008) The neuronal
nicotinic acetylcholine receptors 4* and 6* differentially modulate do-
pamine release in mouse striatal slices. J. Neurochem. 105, 1761–1769
8. Pons, S., Fattore, L., Cossu, G., Tolu, S., Porcu, E., McIntosh, J. M., Chan-
geux, J. P., Maskos, U., and Fratta, W. (2008) Crucial role of 4 and 6
nicotinic acetylcholine receptor subunits from ventral tegmental area in
systemic nicotine self-administration. J. Neurosci. 28, 12318–12327
9. Jackson, K. J., Martin, B. R., Changeux, J. P., and Damaj, M. I. (2008)
Differential role of nicotinic acetylcholine receptor subunits in physical
and affective nicotine withdrawal signs. J. Pharmacol. Exp. Ther. 325,
302–312
10. Gotti, C., Guiducci, S., Tedesco, V., Corbioli, S., Zanetti, L., Moretti, M.,
Zanardi, A., Rimondini, R., Mugnaini, M., Clementi, F., Chiamulera, C.,
and Zoli, M. (2010) Nicotinic acetylcholine receptors in the mesolimbic
pathway: primary role of ventral tegmental area 62* receptors in medi-
ating systemic nicotine effects on dopamine release, locomotion, and re-
inforcement. J. Neurosci. 30, 5311–5325
11. Booker, T. K., Butt, C. M., Wehner, J. M., Heinemann, S. F., and Collins,
A. C. (2007) Decreased anxiety-like behavior in 3 nicotinic receptor sub-
unit knockout mice. Pharmacol. Biochem. Behav. 87, 146–157
12. Drenan, R. M., Grady, S. R., Steele, A. D., McKinney, S., Patzlaff, N. E.,
McIntosh, J. M., Marks, M. J., Miwa, J. M., and Lester, H. A. (2010) Cho-
linergic modulation of locomotion and striatal dopamine release is medi-
ated by 64* nicotinic acetylcholine receptors. J. Neurosci. 30,
9877–9889
13. Drenan, R.M.,Grady, S. R.,Whiteaker, P.,McClure-Begley, T.,McKinney,
S.,Miwa, J.M., Bupp, S., Heintz, N.,McIntosh, J.M., Bencherif,M.,Marks,
M. J., and Lester, H. A. (2008) In vivo activation of midbrain dopamine
neurons via sensitized, high affinity 6 nicotinic acetylcholine receptors.
Neuron 60, 123–136
14. Gotti, C., Moretti, M., Clementi, F., Riganti, L., McIntosh, J. M., Collins,
A. C., Marks, M. J., and Whiteaker, P. (2005) Expression of nigrostriatal
6-containing nicotinic acetylcholine receptors is selectively reduced, but
not eliminated, by 3 subunit gene deletion. Mol. Pharmacol. 67,
2007–2015
15. Dash, B., Chang, Y., and Lukas, R. J. (2011) Reporter mutation studies
show that nicotinic acetylcholine receptor (nAChR) 5 subunits and/or
variants modulate function of 6*-nAChR. J. Biol. Chem. 286,
37905–37918
16. Fucile, S., Matter, J. M., Erkman, L., Ragozzino, D., Barabino, B., Grassi, F.,
Alema` , S., Ballivet, M., and Eusebi, F. (1998) The neuronal 6 subunit
forms functional heteromeric acetylcholine receptors in human trans-
fected cells. Eur. J. Neurosci. 10, 172–178
17. Evans, N. M., Bose, S., Benedetti, G., Zwart, R., Pearson, K. H., McPhie,
G. I., Craig, P. J., Benton, J. P., Volsen, S. G., Sher, E., and Broad, L. M.
(2003) Expression and functional characterization of a human chimeric
nicotinic receptor with 64 properties. Eur. J. Pharmacol. 466, 31–39
18. Gerzanich, V., Kuryatov, A., Anand, R., and Lindstrom, J. (1997) “Orphan”
6 nicotinic AChR subunit can form a functional heteromeric acetylcho-
line receptor.Mol. Pharmacol. 51, 320–327
19. Kuryatov, A., Olale, F., Cooper, J., Choi, C., and Lindstrom, J. (2000) Hu-
man 6 AChR subtypes: subunit composition, assembly, and pharmaco-
logical responses. Neuropharmacology 39, 2570–2590
20. Kuryatov, A., and Lindstrom, J. (2011) Expression of functional human
623* acetylcholine receptors in Xenopus laevis oocytes achieved
through subunit chimeras and concatamers. Mol. Pharmacol. 79,
126–140
21. Broadbent, S., Groot-Kormelink, P. J., Krashia, P. A., Harkness, P. C., Mil-
lar, N. S., Beato, M., and Sivilotti, L. G. (2006) Incorporation of the 3
subunit has a dominant-negative effect on the function of recombinant
central-type neuronal nicotinic receptors. Mol. Pharmacol. 70,
1350–1357
22. Tumkosit, P., Kuryatov, A., Luo, J., and Lindstrom, J. (2006) 3 subunits
promote expression and nicotine-induced up-regulation of human nico-
tinic 6* nicotinic acetylcholine receptors expressed in transfected cell
lines.Mol. Pharmacol. 70, 1358–1368
23. Kuryatov, A., Onksen, J., and Lindstrom, J. (2008) Roles of accessory sub-
units in 42* nicotinic receptors.Mol. Pharmacol. 74, 132–143
24. Groot-Kormelink, P. J., Boorman, J. P., and Sivilotti, L. G. (2001) Forma-
tion of functional345 humanneuronal nicotinic receptors inXenopus
oocytes: a reporter mutation approach. Br. J. Pharmacol. 134, 789–796
25. Li, P., McCollum,M., Bracamontes, J., Steinbach, J. H., and Akk, G. (2011)
Functional characterization of the 5(Asn-398) variant associated with
risk for nicotine dependence in the345 nicotinic receptor.Mol. Phar-
macol. 80, 818–827
26. Labarca, C.,Nowak,M.W., Zhang,H., Tang, L., Deshpande, P., andLester,
H. A. (1995) Channel gating governed symmetrically by conserved leucine
residues in the M2 domain of nicotinic receptors. Nature 376, 514–516
27. Miko, A., Werby, E., Sun, H., Healey, J., and Zhang, L. (2004) A TM2
residue in the 1 subunit determines spontaneous opening of homomeric
and heteromeric -aminobutyric acid-gated ion channels. J. Biol. Chem.
279, 22833–22840
28. Chang, Y., and Weiss, D. S. (1998) Substitutions of the highly conserved
M2 leucine create spontaneously opening rho1 -aminobutyric acid re-
ceptors.Mol. Pharmacol. 53, 511–523
29. Wang, N., Orr-Urtreger, A., Chapman, J., Rabinowitz, R., Nachman, R.,
and Korczyn, A. D. (2002) Autonomic function in mice lacking 5 neuro-
nal nicotinic acetylcholine receptor subunit. J. Physiol. 542, 347–354
30. Salas, R., Orr-Urtreger, A., Broide, R. S., Beaudet, A., Paylor, R., and De
Biasi, M. (2003) The nicotinic acetylcholine receptor subunit 5mediates
short-term effects of nicotine in vivo.Mol. Pharmacol. 63, 1059–1066
31. Wang, N., Orr-Urtreger, A., Chapman, J., Rabinowitz, R., and Korczyn,
A. D. (2004) Nicotinic acetylcholine receptor 5 subunits modulate ox-
otremorine-induced salivation and tremor. J. Neurol. Sci. 222, 87–91
Gain-of-function6*-Nicotinic Receptor and3 Subunits
APRIL 20, 2012•VOLUME 287•NUMBER 17 JOURNAL OF BIOLOGICAL CHEMISTRY 14269
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Bhagirathi Dash and Ronald J. Lukas
Subunits
3β6*-Nicotinic Acetylcholine Receptor by αModulation of Gain-of-function 
doi: 10.1074/jbc.M111.322610 originally published online February 7, 2012
2012, 287:14259-14269.J. Biol. Chem. 
  
 10.1074/jbc.M111.322610Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/287/17/14259.full.html#ref-list-1
This article cites 31 references, 19 of which can be accessed free at
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
